Allakos (ALLK) is embroiled in a clinical trial controversy with potentially billions of dollars at stake.
The San Francisco Bay Area biotech is using a Phase 1 clinical trial to collect safety and tolerability data on its lead digestive disease drug, called antolimab. The existence of this trial — which Allakos has not told investors about — raises questions about a promise already made to move antolimab into a pivotal Phase 3 clinical trial before the end of March.
About the Author Reprints
